<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Isradipine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Isradipine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Isradipine: Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="8585" href="/d/html/8585.html" rel="external">see "Isradipine: Drug information"</a> and <a class="drug drug_patient" data-topicid="10778" href="/d/html/10778.html" rel="external">see "Isradipine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F1020781"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antihypertensive Agent</span>;</li>
<li>
<span class="list-set-name">Calcium Channel Blocker</span>;</li>
<li>
<span class="list-set-name">Calcium Channel Blocker, Dihydropyridine</span></li></ul></div>
<div class="block dop drugH1Div" id="F4476167"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Hypertension: </b>Limited data available: Children and Adolescents: Oral: Immediate release: Initial: 0.05 to 0.1 mg/kg/dose 2 to 3 times daily; titrate upwards at 2- to 4-week intervals; maximum daily dose: 0.6 mg/kg/<b>day</b> or 10 mg/<b>day</b> (whichever is lower) (AAP [Flynn 2017]). Based on retrospective observations, initial doses of 0.05 to 0.15 mg/kg/dose administered 3 to 4 times daily have been suggested in patients with secondary hypertension and acute severe hypertension; usual daily dose: 0.3 to 0.4 mg/kg/day in divided doses (eg, every 8 hours); reported range: 0.04 to 1.2 mg/kg/day (Flynn 2002; Flynn 2009; Johnson 1997; Miyashita 2010; Strauser 2000). <b>Note:</b> Most adult patients show no improvement with doses &gt;10 mg daily and adverse reaction rate increases.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51128358"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; however, bioavailability is increased with mild renal impairment; trend is reversed with further renal function deterioration. Other sources recommend that no initial dosage adjustment is required in pediatric and adult patients (Aronoff 2007). Isradipine is not removed by hemodialysis; therefore, supplemental doses after hemodialysis are not necessary (Schönholzer 1992).</p></div>
<div class="block dohp drugH1Div" id="F51284052"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; however, adult pharmacokinetic data has shown peak serum concentrations are increased by 32% and bioavailability is increased by 52%; use with caution.</p></div>
<div class="block doa drugH1Div" id="F185333"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8585" href="/d/html/8585.html" rel="external">see "Isradipine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f0c92d9-ad08-4643-a848-3296ddf5258e">Hypertension, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For patients who warrant combination therapy (BP &gt;20/10 mm Hg above goal or suboptimal response to monotherapy), may use with another appropriate agent (eg, angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, or thiazide diuretic) (ACC/AHA [Whelton 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 2.5 mg twice daily; evaluate response after ~2 to 4 weeks and titrate dose as needed up to 5 mg twice daily; if additional BP control is needed, consider combination therapy (ACC/AHA [Whelton 2018]). <b>Note:</b> Most patients show no additional response with doses &gt;10 mg/day and adverse reactions occur more frequently.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50992092"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, bioavailability is increased with mild renal impairment and decreased with severe renal impairment. Isradipine is not removed by hemodialysis; therefore, supplemental doses after hemodialysis are not necessary (Schönholzer 1992).</p></div>
<div class="block doha drugH1Div" id="F50989308"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, peak serum concentrations are increased by 32% and AUC is increased by 52%.</p></div>
<div class="block adr drugH1Div" id="F185297"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Central nervous system: Headache (dose related 2% to 22%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (dose related 1% to 9%), flushing (dose related 1% to 5%), palpitations (dose related 1% to 5%), chest pain (3%), tachycardia (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Fatigue (dose related ≤9%), dizziness (2% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (3% to 5%), abdominal distress (≤3%), diarrhea (≤3%), vomiting (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Weakness (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Urinary frequency (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Atrial fibrillation, cardiac failure, cerebrovascular accident, constipation, cough, decreased libido, depression, drowsiness, foot cramps, hyperhidrosis, hypotension, impotence, increased liver enzymes, insomnia, leg cramps, lethargy, leukopenia, myocardial infarction, nervousness, nocturia, numbness, paresthesia, pruritus, psoriasis (Song 2021), sore throat, syncope, transient ischemic attacks, urticaria, ventricular fibrillation, visual disturbance, xerostomia</p></div>
<div class="block coi drugH1Div" id="F185311"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to isradipine or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F185294"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Angina/MI: Increased angina and/or MI has occurred with initiation or dosage titration of dihydropyridine calcium channel blockers. Reflex tachycardia may occur resulting in angina and/or MI in patients with obstructive coronary disease, especially in the absence of concurrent beta-blockade.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension/syncope: Symptomatic hypotension with or without syncope can rarely occur; blood pressure must be lowered at a rate appropriate for the patient's clinical condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peripheral edema: A common side effect is peripheral edema (dose-dependent); may begin within 2 to 3 weeks of starting therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aortic stenosis: Use with extreme caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure (HF): The AHA/ACC/HFSA heart failure guidelines recommend to avoid use in patients with heart failure due to lack of benefit and/or worse outcomes with calcium channel blockers in general (AHA/ACC/HFSA [Heidenreich 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; may require lower starting dose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.</p></div>
<div class="block foc drugH1Div" id="F185303"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg</p></div>
<div class="block geq drugH1Div" id="F185290"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F185313"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Isradipine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $1.90 - $12.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $2.78 - $12.34</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block exp drugH1Div" id="F185309"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">A 1 mg/mL oral suspension may be made from isradipine capsules; glycerin, USP; and Simple Syrup, N.F. Empty the contents of ten 5 mg isradipine capsules into a glass mortar. Add a small portion of glycerin, USP and mix to a fine paste; mix while adding 15 mL of simple syrup and transfer contents to a 60 mL amber glass prescription bottle. Rinse mortar with 10 mL simple syrup, NF and transfer to the prescription bottle; repeat, and add quantity of vehicle sufficient to make 50 mL. Label "protect from light", "refrigerate", and "shake well". Stable for 35 days when stored in amber glass prescription bottles in the dark and refrigerated.</p>
<div class="reference">MacDonald JL, Johnson CE, and Jacobson P, “Stability of Isradipine in Extemporaneously Compounded Oral Liquids,” <i>Am J Hosp Pharm</i>, 1994, 51(19):2409-11.<span class="pubmed-id">7847406</span></div>
</div>
<div class="block admp drugH1Div" id="F52613101"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be administered without regard to meals.</p></div>
<div class="block adm drugH1Div" id="F185307"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: May be administered without regard to meals.</p></div>
<div class="block sts drugH1Div" id="F21658773"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F) in a tight container, protected from moisture, humidity, and light.</p></div>
<div class="block usep drugH1Div" id="F53567428"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of hypertension alone or in combination with thiazide-type diuretics (FDA approved in adults) </p></div>
<div class="block cyt drugH1Div" id="F185363"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F185299"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Isradipine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Isradipine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Isradipine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Isradipine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dantrolene: May enhance the hyperkalemic effect of Calcium Channel Blockers. Dantrolene may enhance the negative inotropic effect of Calcium Channel Blockers.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the orthostatic hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: Isradipine may increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Isradipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhalational Anesthetics: May enhance the hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the adverse/toxic effect of Calcium Channel Blockers (Dihydropyridine). Specifically, the risk of hypotension or muscle weakness may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F185325"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Administration with food delays absorption, but does not affect availability. Management: Administer without regard to meals.</p></div>
<div class="block rep_considerations drugH1Div" id="F58493565"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be continued in patients trying to conceive. Isradipine is generally not considered a preferred agent for use during pregnancy (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019); however, use may be considered (ESC [Cífková 2020]).</p></div>
<div class="block pri drugH1Div" id="F185314"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Isradipine crosses the human placenta. In a study of 16 women, umbilical cord concentrations were variable but less than maternal serum (Lunell 1993).</p>
<p style="text-indent:0em;margin-top:2em;">Chronic maternal hypertension is associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of oral isradipine may be altered (Christensen 1994).</p>
<p style="text-indent:0em;margin-top:2em;">Patients with preexisting hypertension may continue their medication during pregnancy unless contraindications exist (ESC [Regitz-Zagrosek 2018]). When treatment of hypertension is initiated during pregnancy, agents other than isradipine may be preferred (ACOG 2019; ESC [Regitz-Zagrosek 2018]; SOGC [Magee 2022]); however, use of isradipine may be considered (ESC [Cífková 2020]).</p></div>
<div class="block mopp drugH1Div" id="F53567420"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;text-align:justify;display:inline">Blood pressure, heart rate, liver and renal function </p></div>
<div class="block pha drugH1Div" id="F185293"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits calcium ion from entering the “slow channels” or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization, producing relaxation of vascular smooth muscle, resulting in coronary vasodilation and reduced blood pressure; increases myocardial oxygen delivery in patients with vasospastic angina</p></div>
<div class="block phk drugH1Div" id="F185310"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: 2 to 3 hours; <b>Note:</b> Full hypotensive effect may not occur for 2 to 4 weeks</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: &gt;12 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: 90% to 95%, but large first-pass effect</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 3 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 95%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensive first-pass effect; hepatically metabolized via cytochrome P450 isoenzyme CYP3A4; major metabolic pathways include oxidation and ester cleavage; six inactive metabolites have been identified</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 15% to 24%</p>
<p style="text-indent:-2em;margin-left:4em;">Mild renal impairment (CrCl 30 to 80 mL/minute): Increased by 45%; as renal function continues to decline, this increase in AUC is reversed to a reduction in AUC as seen with severe renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe renal impairment (CrCl &lt;10 mL/minute); concurrent hemodialysis: Decreased by 20% to 50%</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic impairment: Increased by 52%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Alpha half-life: 1.5 to 2 hours; Terminal half-life: 8 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: 1 to 1.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (60% to 65% as metabolites); feces (25% to 30%)</p></div>
<div class="block phksp drugH1Div" id="F51193256"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: The C<sub>max</sub> increases by 32%</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: The AUC and C<sub>max</sub> increases.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F185316"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Lomir</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Dynacirc</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Lomir</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Lomir</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Lomir</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Lomir</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Dynacirc</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Dynacirc</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Lomir</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Lomir | Vascal</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Lomir</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Dynacirc</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Dynacirc</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Lomir</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Lomir</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Lomir</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Icaz</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Lomir</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Dynacirc</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Lomir</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Clivoten | Esradin | Isradipina provvisoria | Lomir</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Lomir</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dynacirc</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Lomir</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Lomir</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Icaz</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Dynacirc</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Dynacirc</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Lomir</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Lomir sro</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Dynacirc</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Dynacirc</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Dynacirc | Icaz</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Lomir</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Dynacirc</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Dilatol | Lomir</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Lomir</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Lomir</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Lomir</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Tenzipin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Dynacirc</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Icaz</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Dynacirc</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Dynacirc</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dynacirc</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Dynacirc</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 203: chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isradipine-pediatric-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23630129">
<a name="23630129"></a>Anderson JL, Adams CD, Antman EM, et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(23):e663-e828.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isradipine-pediatric-drug-information/abstract-text/23630129/pubmed" id="23630129" target="_blank">23630129</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 40.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12748199">
<a name="12748199"></a>Chobanian AV, Bakris GL, Black HR, et al, “The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,” <i>JAMA</i>, 2003, 289(19):2560-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isradipine-pediatric-drug-information/abstract-text/12748199/pubmed" id="12748199" target="_blank">12748199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7769498">
<a name="7769498"></a>Christensen HR, Skajaa K, Angelo HR, et al. Reduced bioavailability of the calcium antagonist isradipine (Lomir Retard) in pregnant patients. Abstract presented at: 15th Scientific Meeting of the International Society of Hypertension; March 20-24, 1994; Melbourne, Australia. <i>J Hypertens Suppl.</i> 1994;12(3):168.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isradipine-pediatric-drug-information/abstract-text/7769498/pubmed" id="7769498" target="_blank">7769498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31841131">
<a name="31841131"></a>Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. <i>Eur Heart J Cardiovasc Pharmacother</i>. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isradipine-pediatric-drug-information/abstract-text/31841131/pubmed" id="31841131" target="_blank">31841131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al, “2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,” <i>Circulation</i>, 2012, 126(25):3097-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isradipine-pediatric-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28827377">
<a name="28827377"></a>Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. <i>Pediatrics</i>. 2017;140(3). pii: e20171904.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isradipine-pediatric-drug-information/abstract-text/28827377/pubmed" id="28827377" target="_blank">28827377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11149130">
<a name="11149130"></a>Flynn JT and Pasko DA, "Calcium Channel Blockers: Pharmacology and Place in Therapy of Pediatric Hypertension," <i>Pediatr Nephrol</i>, 2000, 15(3-4):302-16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isradipine-pediatric-drug-information/abstract-text/11149130/pubmed" id="11149130" target="_blank">11149130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18839219">
<a name="18839219"></a>Flynn JT, Tullus K. Severe hypertension in children and adolescents: pathophysiology and treatment. <i>Pediatr Nephrol</i>. 2009;24(6):1101-1112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isradipine-pediatric-drug-information/abstract-text/18839219/pubmed" id="18839219" target="_blank">18839219</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Flynn JT and Warnick SJ, "Isradipine Treatment of Hypertension in Children: A Single-Center Experience," <i>Pediatr Nephrol</i>, 2002, 17(9):748-53.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isradipine-pediatric-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24243703">
<a name="24243703"></a>Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isradipine-pediatric-drug-information/abstract-text/24243703/pubmed" id="24243703" target="_blank">24243703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isradipine-pediatric-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Isradipine.1">
<a name="Isradipine.1"></a>Isradipine capsules, USP [prescribing information]. Northvale, NJ: Elite Laboratories Inc; December 2022.</div>
</li>
<li>
<div class="reference">
                  Isradipine [package insert]. Mahwah, NJ: Glenmark Pharmaceuticals Inc, USA; October 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352797">
<a name="24352797"></a>James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isradipine-pediatric-drug-information/abstract-text/24352797/pubmed" id="24352797" target="_blank">24352797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9184708">
<a name="9184708"></a>Johnson CE, Jacobson PA, and Song MH, "Isradipine Therapy in Hypertensive Pediatric Patients," <i>Ann Pharmacother</i>, 1997, 31(6):704-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isradipine-pediatric-drug-information/abstract-text/9184708/pubmed" id="9184708" target="_blank">9184708</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33637192">
<a name="33637192"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease.<i> Kidney Int.</i> 2021;99(3S):S1-S87. doi:10.1016/j.kint.2020.11.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isradipine-pediatric-drug-information/abstract-text/33637192/pubmed" id="33637192" target="_blank">33637192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8466718">
<a name="8466718"></a>Lunell NO, Bondesson U, Grunewald C, et al, “Transplacental Passage of Isradipine in the Treatment of Pregnancy-Induced Hypertension,” <i>Am J Hypertens</i>, 1993, 6(3 Pt 2):110S-111S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isradipine-pediatric-drug-information/abstract-text/8466718/pubmed" id="8466718" target="_blank">8466718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35577426">
<a name="35577426"></a>Magee LA, Smith GN, Bloch C, et al. Guideline no. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. <i>J Obstet Gynaecol Can.</i> 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isradipine-pediatric-drug-information/abstract-text/35577426/pubmed" id="35577426" target="_blank">35577426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21054771">
<a name="21054771"></a>Miyashita Y, Peterson D, Rees JM, Flynn JT. Isradipine for treatment of acute hypertension in hospitalized children and adolescents. <i>J Clin Hypertens (Greenwich)</i>. 2010;12(11):850-855.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isradipine-pediatric-drug-information/abstract-text/21054771/pubmed" id="21054771" target="_blank">21054771</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents. <i>Clinical Practice Guidelines</i>. 2011. Available at <a href="http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf" target="_blank">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15286277">
<a name="15286277"></a>National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, “The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,” <i>Pediatrics</i>, 2004, 114(2 Suppl):555-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isradipine-pediatric-drug-information/abstract-text/15286277/pubmed" id="15286277" target="_blank">15286277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2019">
<a name="NICE.2019"></a>NICE guideline hypertension in pregnancy: diagnosis and management. https://www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24589852">
<a name="24589852"></a>Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isradipine-pediatric-drug-information/abstract-text/24589852/pubmed" id="24589852" target="_blank">24589852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isradipine-pediatric-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1535593">
<a name="1535593"></a>Schönholzer K and Marone C, Pharmacokinetics and dialysability of isradipine in chronic haemodialysis patients. <i>Eur J Clin Pharmacol</i>. 1992;42(2):231-233.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isradipine-pediatric-drug-information/abstract-text/1535593/pubmed" id="1535593" target="_blank">1535593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34611920">
<a name="34611920"></a>Song G, Yoon HY, Yee J, Kim MG, Gwak HS. Antihypertensive drug use and psoriasis: a systematic review, meta- and network meta-analysis. <i>Br J Clin Pharmacol</i>. Published online October 5, 2021. doi:10.1111/bcp.15060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isradipine-pediatric-drug-information/abstract-text/34611920/pubmed" id="34611920" target="_blank">34611920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10728516">
<a name="10728516"></a>Strauser LM, Groshong T, and Tobias JD, "Initial Experience With Isradipine for the Treatment of Hypertension in Children," <i>South Med J</i>, 2000, 93(3):287-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isradipine-pediatric-drug-information/abstract-text/10728516/pubmed" id="10728516" target="_blank">10728516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24341872">
<a name="24341872"></a>Weber MA, Schiffrin EL, White WB, et al, Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isradipine-pediatric-drug-information/abstract-text/24341872/pubmed" id="24341872" target="_blank">24341872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9249636">
<a name="9249636"></a>Westbrook P, Bednarczyk EM, Carlson M, et al, “Regression of Nifedipine-Induced Gingival Hyperplasia Following Switch to a Same Class Calcium Channel Blocker, Isradipine,” <i>J Periodontol</i>, 1997, 68(7):645-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isradipine-pediatric-drug-information/abstract-text/9249636/pubmed" id="9249636" target="_blank">9249636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. <i>Hypertension</i>. 2018;71(6):e13-e115. doi:10.1161/HYP.0000000000000065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isradipine-pediatric-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12890 Version 271.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
